Corcept Therapeutics | CORT - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Alaunos Therapeutics USD 1.38M 553K 2025-12
ANI Pharmaceuticals USD 285.58M 22.98M 2025-12
Ardelyx USD 31.21M 36.79M 2026-03
Assertio Holdings USD 38.5M 8.59M 2025-09
Aurora Cannabis CAD 56.36M 39.33M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Canopy Growth CAD 371.32M 73.26M 2025-12
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 92.45M 6.39M 2025-09
J&J USD 21.69B 1.98B 2026-03
Knight Therapeutics CAD 76.45M 5.43M 2025-12
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Merck USD 14.57B 3.6B 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Novartis USD 11.44B 1.88B 2025-12
Novartis USD 9.56B 2.9B 2025-09
Omeros USD 1.9M 2.36M 2025-06
Pacira USD 144.31M 14.24M 2026-03
Pfizer USD 1.34B 295M 2025-09
Supernus Pharmaceuticals USD 151.37M 6.66M 2025-09
TG Therapeutics USD 199.51M 21.2M 2025-12